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Cooling to 33.5 °C in babieswith neonatal encephalopathy signiﬁcantly reduces death and disability, however ad-
ditional therapies are needed to maximize brain protection. Following hypoxia–ischemia we assessed whether
inhaled 45–50% Argon from 2–26 h augmented hypothermia neuroprotection in a neonatal piglet model, using
MRS and aEEG,which predict outcome inbabieswith neonatal encephalopathy, and immunohistochemistry. Fol-
lowing cerebral hypoxia–ischemia, 20 Newbornmale LargeWhite piglets b 40 hwere randomized to: (i) Cooling
(33 °C) from 2–26 h (n=10); or (ii) Cooling and inhaled 45–50% Argon (Cooling+Argon) from 2–26 h (n=8).
Whole-brain phosphorus-31 and regional proton MRS were acquired at baseline, 24 and 48 h after hypoxia–is-
chemia. EEG was monitored. At 48 h after hypoxia–ischemia, cell death (TUNEL) was evaluated over 7 brain re-
gions. Therewere no differences in bodyweight, duration of hypoxia–ischemia or insult severity; throughout the
study there were no differences in heart rate, arterial blood pressure, blood biochemistry and inotrope support.
Two piglets in the Cooling + Argon group were excluded. Comparing Cooling + Argon with Cooling there was
preservation of whole-brain MRS ATP and PCr/Pi at 48 h after hypoxia–ischemia (p b 0.001 for both) and
lower 1H MRS lactate/N acetyl aspartate in white (p = 0.03 and 0.04) but not gray matter at 24 and 48 h. EEG
background recovery was faster (p b 0.01) with Cooling + Argon. An overall difference between average cell-
death of Cooling versus Cooling + Argon was observed (p b 0.01); estimated cells per mm2 were 23.9 points
lower (95% C.I. 7.3–40.5) for the Cooling+Argon versus Cooling. Inhaled 45–50% Argon from2–26 h augmented
hypothermic protection at 48 h after hypoxia–ischemia shown by improved brain energy metabolism on MRS,
faster EEG recovery and reduced cell death on TUNEL. Argon may provide a cheap and practical therapy to aug-
ment cooling for neonatal encephalopathy.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
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1. Introduction
Neonatal Encephalopathy (NE) consequent on perinatal hypoxia–is-
chemia is the third leading cause of child death and one of the main
causes of preventable child neurodisability worldwide (Lawn et al.,
2014). In the developedworld, cooling to 33–34 °C for 72 h inmoderate
to severe NE increases the rate of survivalwithout impairments in child-
hood to 15%, but despite cooling, around 25% infants die and 20% survi-
vors have sensorimotor or cognitive impairments (Azzopardi et al.,
2014). Attempts to increase brain protection with deeper and longer
cooling (Alonso-Alconada et al., 2015; Shankaran et al., 2014) suggest
that current clinical cooling protocols are optimal and that other thera-
pies that can augment hypothermic neuroprotection in NE are needed
(Robertson et al., 2012).
In a comparative review of potential neuroprotective agents, the
noble gas Xenon was rated in the top six, however there was concern
over its cost and the requirement for specialized equipment for delivery
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and scavenging (Robertson et al., 2012). Xenon has shownneuroprotec-
tive properties in adult and neonatal (Chakkarapani et al., 2010;
Faulkner et al., 2011; Ma et al., 2005) models of hypoxia–ischemia;
this neuroprotection is stronger in neonatal models when Xenon is
combined with cooling. In neonatal rat (Ma et al., 2005) and piglet
(Chakkarapani et al., 2010; Faulkner et al., 2011) studies, the combina-
tion of Xenon with cooling provided neuroprotection while neither in-
tervention alone was as effective. Current interest is turning towards
Argon, which is the most abundant inert gas already widely used in in-
dustries and available at a cost 200 times lower than Xenon. Argon does
not produce demonstrable anesthetic effects at atmospheric pressure
and provides potent neuroprotection, at least equivalent to Xenon, in
animal models of hypoxic–ischemic brain injury and in vitro using mu-
rine organotypic hippocampal slice cultures (Loetscher et al., 2009) and
neuronal cultures (Jawad et al., 2009). In some studies Argon is superior
to Xenon for organ protection from ischemia-reperfusion injury (Irani
et al., 2011). In vitromodels of cerebral ischemia and traumatic brain in-
jury suggest that the optimum concentration of Argon for protection is
50% and the therapeutic window lasts up to 3 h (Loetscher et al.,
2009). Argon 50% administered one hour after transientmiddle cerebral
artery occlusion (MCAO) in adult rats provided signiﬁcantly reduced in-
farct volumes and composite adverse outcomes (Ryang et al., 2011).
Protection has also been observed in neonatal rodent models where
70% argon at 2 h after hypoxia–ischemia improved cell survival to
naive levels and reduced infarct volume (Zhuang et al., 2012).
We hypothesized that Argon-augmented cooling would lead to bet-
ter brain protection than cooling alone after a hypoxic–ischemic insult.
Our aim was to assess whether 24 h of 45–50% Argon started 2 h after
hypoxia–ischemia augments hypothermic neuroprotection in a piglet
perinatal asphyxia model. This model replicates neonatal intensive
care with meticulous monitoring and control of physiological and met-
abolic parameters. This model also has strong similarities to newborn
infants with NE in terms of the timing of the evolution of injury after
hypoxia–ischemia (Azzopardi et al., 1989; Lorek et al., 1994), pattern
of injury, neuropathology and cerebral magnetic resonance spectros-
copy (MRS) (Thayyil et al., 2010). The efﬁcacy of Argon protection was
assessed using: (i) Cerebral MRS biomarkers, proton (1H) MRS lactate/
N acetyl aspartate (NAA) (Thayyil et al., 2010) and phosphorus-31
(31P) MRS for phosphocreatine/inorganic phosphate (PCr/Pi) and NTP/
exchangeable phosphate pool (epp) (Azzopardi et al., 1989); (ii) aEEG
background activity recovery over 48 h, a strong predictor of outcome
in babies with NE (van Rooij et al., 2005); and (iii) Histological assess-
ment of cell death using TUNEL at 48 h after hypoxia–ischemia.
2. Materials and methods
2.1. Sample size calculation
Our primary outcomes were cerebral lactate/NAA and NTP/epp. Pre-
vious work with our model suggested that the change in lactate/NAA
during 48 h varied between normo- and hypothermic groups by 1.0 U,
with a standard deviation of 0.65U (log scale). Assuming similarmagni-
tude of additional effect for Argon-augmented cooling following HI ver-
sus cooling alone and similar variability at 48 h andwith 5% signiﬁcance
and 80% power, at least eight subjects were required in each group
based on a two-sample t-test sample size calculation.
2.2. Animal experiments and surgical preparation
All animal experiments were approved by the Ethics Committee of
UCL and performed according to the UK Home Ofﬁce Guidelines [Ani-
mals (Scientiﬁc procedures) Act, 1986]. The study complies with the
ARRIVE guidelines. Twenty male piglets, aged less than 40 h, with
weights 1.8–2.1 kg were anesthetized and surgically prepared as de-
scribed previously (Lorek et al., 1994). The study time-line is shown in
Fig. 1. Anesthesia was induced by 4% v/v isoﬂurane through a facemask
for around 5 min to facilitate tracheostomy and intubation. Throughout
the surgery, isoﬂurane was maintained at 2.8–3% guided by peripheral
oxygen saturation monitoring (Nonin Medical, Plymouth, MN, USA)
and the animal's response to stimulation. Following tracheostomy, a
suitable size of endotracheal tube (Smiths Medical, Ashford, Kent, UK)
was ﬁxed and the piglet was mechanically ventilated (SLE 2000 infant
ventilator, Surrey, UK). Ventilator settings were adjusted to maintain
partial pressure of oxygen (PaO2) at 8–13 kPa and carbon dioxide
(PaCO2) at 4.5–6.5 kPa, allowing for temperature and fraction of in-
spired oxygen (FiO2) correction of the arterial blood sample.
After the airway was secured, both common carotid arteries were
surgically isolated at the level of the fourth cervical vertebra and a vas-
cular occluder (OC2A, In Vivo Metric, Healdsburg, CA, USA) was placed
on each side. After completion of surgery, inspired isoﬂurane concentra-
tion was maintained at 2% v/v.
An umbilical venous catheter was inserted for infusion of mainte-
nance ﬂuids (10% dextrose, 60 ml/kg/day before the insult and 40 ml/
kg/day after resuscitation), fentanyl (5 μg/kg/h), and antibiotics (benzyl
penicillin 50mg/kg, every 12 h and gentamicin 4mg/kg, once a day). An
umbilical arterial catheter was inserted for invasive physiologic moni-
toring (SA instruments) for heart rate and arterial blood pressure, and
blood sampling for arterial gases and electrolytes (Abbot Laboratories,
UK). Hepsal (0.5 IU/ml of heparin in 0.9% saline solution) was infused
at rate of 0.3 ml/h to prevent umbilical arterial catheter blockage.
Piglets were cared for under intensive care conditions throughout
the experiment. To maintain the MABP above 40 mm Hg, bolus infu-
sions of 0.9% saline (Baxter; 10ml/kg), dopamine (5–20 μg/kg/min), do-
butamine (5–20 μg/kg/min) and adrenaline (0.1–1.5 μg/kg/min) were
used as required by a NICU trained clinician. High serum lactate was
treated by optimizing oxygenation and 0.45% saline bolus infusions.
Hyperkalemia (K N 7.0 mmol/l) was treated with 4 μg/kg salbutamol
(10 μg/ml) over 10 min.
2.3. MR methods
The head was immobilized in a stereotactic frame for MRS acquisi-
tion. Piglets were positioned within the bore of 9.4 Tesla Agilent MR
scanner. 1H and 31P MRS data were acquired at baseline and at 24 and
48 h after cerebral hypoxic-ischemia.
2.3.1. 31P MRS
A 7 cm × 5 cm elliptical transmit-receive MRS surface coil tuned to
the 31P resonant frequency was positioned on top of the head. 31P
MRS was acquired with 1-minute resolution using a non-localized
single-pulse acquisition. MRS data were analyzed using the Advanced
Method for Accurate, Robust and Efﬁcient Spectral ﬁtting of MRS data
with use of prior knowledge (AMARES) (Vanhamme et al., 1997) as im-
plemented in the jMRUI software. Prior knowledge of NTP multiplet
structurewas used. NTP is predominately ATP and the latter contributes
approximately 70% of the NTP signal (Mandel and Edel-Harth, 1966).
Thus NTP changes during this experiment predominately reﬂected
ATP changes. Pi was ﬁtted using 4 separate components and PCr with
a single component. The following peak-area ratios were calculated:
Pi/epp, PCr/epp, and NTP/epp where epp = exchangeable phosphate
pool = Pi + PCr + 2γ-NTP + β-NTP.
2.3.2. 1H MRS
1H MRS data were collected from voxels located in the dorsal right
subcortical white matter at the centrum semiovale level (white matter
voxel, 8 × 8 × 15mm) and in the deep graymatter centered on both lat-
eral thalami (deep graymatter voxel, 15 × 15 × 10mm) using a combi-
nation of a 65×55mmelliptical receive surface coil, a 150mmdiameter
transmit volume coil and a LASER acquisition (TR = 5000 ms, TE =
288ms, 128 averages). Spectra were analyzed using AMARES as imple-
mented in the jMRUI software and the lactate/NAA peak area ratio was
calculated.
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2.4. Cerebral hypoxia–ischemia (HI)
31P MRS data were collected at baseline, during hypoxia–ischemia
and for one hour after cessation of hypoxia–ischemia. Hypoxia–ische-
miawas induced inside theMR scanner by remotely inﬂating the vascu-
lar occluders around both common-carotid arteries, and simultaneously
reducing FiO2 to 6% (vol/vol). During hypoxia–ischemia the β-NTP
peak height was continuously monitored using in-house Matlab
(Mathworks) software. At the point at which β-NTP had fallen to 50%
of its baseline value, FiO2 was increased to 9%. When β-NTP fell to 40%
baseline height the inspired oxygen fraction was titrated to keep the
β-NTP peak height between 30% and 40% of its original height for a pe-
riod of 12.5 min. At the end of hypoxia–ischemia the carotid arteries
were de-occluded and the FiO2 returned to 21%. Insult severity was cal-
culated (Faulkner et al., 2011).
2.5. Experimental groups
Following resuscitation, while in the bore of the MR system, piglets
were randomized (computer generated randomization revealed after
HI) into 2 groups — Cooling or Cooling + Argon (Fig. 1). Both groups
were cared for over 48 h after hypoxia–ischemia and maintained hypo-
thermic (core temperature 33.5 °C) between 2–26 h. Physiological pa-
rameters were compared between groups with Mann–Whitney at
each time point.
2.6. Argon delivery
In those randomized to Cooling + Argon, 45–50% Argon was deliv-
ered through the ventilator from 2–26 h (Fig. 1). Argon Gas was ob-
tained from Air Liquide Ltd. (Manchester UK). Piglets were ventilated
via an SLE 2000 infant ventilator (SLE Ltd., Surrey, UK), which has
both oxygen and air supply inlets with an oxygen blender. During
Argon treatment, the air supply was switched with an Argon cylinder
connected inline with the ventilator (Fig. 2). When FiO2 was increased
to maintain piglet peripheral oxygen saturations and PaO2 within
normal parameters, the ventilator blender increased the oxygen deliv-
ery and decreased delivery from the Argon cylinder, resulting in a
small reduction in inspired Argon and Nitrogen concentrations. No
piglet required more than 30% FiO2 therefore all piglets in the
Cooling + Argon group received a minimum of 45% Argon throughout
treatment.
Fig. 1. Study time-line. Following baseline data acquisition, piglets underwent cerebral hypoxia–ischemia. At the end of hypoxia–ischemia (time 0), piglets were randomized to (i) Cooling
(33.5 °C) for 24 h or (ii) Cooling + 50% Argon for 24 h. Treatment was started at 2 h after Time 0. Piglets were maintained under meticulous intensive care for 48 h following HI, prior to
euthanasia. MRS was acquired at baseline, during HI, for the ﬁrst 60 min after HI, at 24 and 48 h. EEG was acquired at baseline and in between the MRS acquisitions.
Fig. 2. Argon delivery. Piglets were ventilated via an SLE2000 infant ventilator (SLE Ltd., Surry, UK) which has both oxygen and air supply inlets with an oxygen blender. Each cylinder
contained 4800 l of compressed gas comprising 50% argon, 21% oxygen and 29% nitrogen. During Argon treatment, the air supply was switched with an Argon cylinder connected inline
with the ventilator. When FiO2 was increased to maintain piglet peripheral oxygen saturations and PaO2 within normal parameters, the ventilator blender increased the oxygen delivery
and decreased the delivery from the Argon cylinder, resulting in a reduction in inspired Argon and Nitrogen concentrations as shown. No piglet required more than 30% FiO2 therefore all
piglets in the Argon + Cooling group received a minimum of 45% Argon throughout treatment.
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2.7. aEEG/EEG acquisition
After surgical preparation, multichannel six-lead EEG monitoring
(Nicolet, Care Fusion, Wisconsin, USA) was acquired at baseline and
throughout the periods between MRS data acquisitions. Filtered
amplitude-integrated EEG recordings were classiﬁed according to the
pattern classiﬁcation (Hellström-Westas et al., 1995). A score of 0 was
ﬂat trace; 1, continuous low voltage; 2, burst suppression; 3, discontin-
uous normal voltage; and 4, continuous normal voltage, at baseline and
then every hour after hypoxia–ischemia.
2.8. Brain histology
At 48 h after hypoxia–ischemia, pigletswere euthanizedwith pento-
barbital, the brain was ﬁxed by cardiac perfusion with cold 4% parafor-
maldehyde, dissected out and post-ﬁxed at 4 °C in 2%
paraformaldehyde for 7 days. Coronal slices (5 mm thick) of the right
hemisphere, starting from anterior to the optic chiasma, were embed-
ded in parafﬁn, sectioned to 8-μm thickness and stained with hematox-
ylin and eosin to validate the bregma for analysis. For each animal, 2
sections (bregma 00 and −2.0) were stained and 7 different regions
in the brain were examined (Fig. 3).
To assess cell death, brain sections were stained for nuclear DNA
fragmentation using histochemistrywith transferasemediated biotinyl-
ated d-UTP nick end-labeling (TUNEL) as previously described
(Robertson et al., 2013). Brieﬂy, TUNEL sections were pretreated in 3%
hydrogen peroxide, subjected to a protease K pre-digestion (Promega,
Southampton, UK) and incubated with TUNEL solution (Roche, Burgess
Hill, UK). TUNEL was visualized using avidin-biotinylated horseradish
complex (ABC, Vector Laboratories, Peterborough, UK) and diamino-
benzidine/H2O2 (DAB, Sigma, Poole, UK) enhanced with CoSO4 and
NiCl2. TUNEL sections were dehydrated and cover-slipped with DPX
(VWR, Leighton Buzzard, UK). For each animal and brain region,
TUNEL-positive nuclei were counted at two levels and from 7 regions
Fig. 3. Histology. Representative piglet brain photomicrograph indicating brain regions assessed for TUNEL immunohistochemistry. 1) Sensorimotor Cortex, sTEX; 2) Cingulate Cortex,
cTEX; 3) Thalamus, THAL; 4) Caudate Nucleus, CDT; 5) Putamen, PTMN; 6) Internal Capsule, IC; 7) Periventricular white matter, pvWM.
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(Fig. 3) by an investigator blind to the treatment group and the average
converted into counts per mm2.
2.9. Statistical methods
2.9.1. MRS
All analyses were performed using the SAS JMP® v11.0.0 software. A
statistical model was ﬁtted to the ratios NTP/epp, PCr/Pi and Lac/NAA.
An analysis of variance (ANOVA) model was ﬁtted and the differences
in themeans on the log scale for the two treatment groups (Cooling ver-
sus Cooling + Argon) were estimated from the model at each of the
three time points with 95% conﬁdence intervals (C.I.s) for the differ-
ences. The differences in treatment groupmeans are shown graphically
using 95% Least Signiﬁcant Difference error bars. Corrections for multi-
ple measurements were not made.
2.9.2. EEG
Following the baseline scoring, scores were obtained hourly until
48 h from hypoxia-ischemia. Each subject's scores were averaged over
the following periods; 0–6 h, 7–12 h, 13–18 h, 19–24 h, 25–30 h, 31–
36 h, 37–42 h and an analysis of variance model ﬁtted to the mean
scores. The differences in themeans between the two treatment groups
(Cooling plus Argon versus Cooling) were estimated from the model at
each of the seven timepoints with 95% conﬁdence intervals (C.I.s) for
the differences.
2.9.3. TUNEL
An analysis of variance model was ﬁtted to the mean counts to give
an estimate of the expected counts per mm2. The overall difference be-
tween the means for the two treatment groups, and treatment differ-
ences across regions are presented with 95% C.I.s and graphically
using 95% Least Signiﬁcant Difference error bars.
3. Results
There were 10 animals in the Cooling group and 8 animals int he
Cooling + Argon group. One piglet (Cooling + Argon) was lost prior
to 48 h due to cardiac arrest. Another piglet (Cooling + Argon) was ex-
cluded because the cooling mattress malfunctioned and the piglet was
normothermic between 7–9 h; in addition a fault was noted in the ven-
tilator and Argon delivery was not assured for a period of several hours.
3.1. Physiological data and insult severity
There were no signiﬁcant intergroup differences between groups
in bodyweight, postnatal age and baseline physiological measures
apart from the base excess, which was more alkaline in the
Cooling + Argon group at baseline (Table 1). There was no difference
in the hypoxic–ischemic insult severity between the two groups
(Table 1). There was no difference between groups for volume replace-
ment and inotrope use following hypoxia-ischemia (Table 2).
3.2. Argon usage
Fifty-four Argon cylinders were used for this study. Each cylinder
contained 4800 l of compressed gas comprising 50% argon; 21% oxygen
and 29% nitrogen. Each cylinder lasted 5.5 h— around 872 l/h or 14.5 l/
min was delivered to the SLE ventilator. The SLE ventilator, however,
vents 8–9 l of air/min leaving the gas delivery to the pig of 4–5 l/min.
3.3. MRS analysis showed improved PCr/Pi, NTP/epp at 48 h and lower
white matter Lac/NAA at 24 and 48 h
The least squares means plots and 95% Least Signiﬁcant Difference
(LSD) bars for the NTP/epp, PCr/Pi and Lac/NAA (on log10 scale) in thal-
amus andwhitematter are shown in Fig. 4. The differences in themeans
Table 1
Baseline group data and physiological variables throughout the studies.
Parameter Cooling
Mean (SD)
Cooling + Argon
Mean (SD)
p value
Postnatal age (h) 29.1 (7.7) 31.0 (8.9) 0.51
Body weight (g) 1978 (109) 1925 (89) 0.19
Duration of HI (min) 24.2 (2.8) 23.0 (1.9) 0.30
Insult severity (10−2) measured
from acute energy depletion (AED)
9.47 (3.14) 8.63 (2.62) 0.63
Heart rate (min−1)
Baseline 175 (20) 165 (23) 0.36
End of insult (time 0) 184 (26) 178 (25) 0.92
1–2 h after time 0 178 (19) 163 (24) 0.12
2–26 h after time 0 154 (14) 158 (20) 0.50
26–48 h after time 0 166 (29) 178 (21) 0.54
Mean arterial blood pressure (mm Hg)
Baseline 47 (8) 45 (7) 0.47
End of insult (time 0) 48 (16) 54 (19) 0.53
1–2 h after time 0 47 (10) 46 (9) 0.70
2–26 h after time 0 46 (3) 46 (7) 0.81
26–48 h after time 0 54 (7) 53 (9) 0.96
Rectal temperature (°C)
Baseline 38.2 (0.7) 38.2 (0.6) 0.96
End of insult (time 0) 37.8 (0.6) 37.9 (0.6) 0.33
1–2 h after time 0 38.2 (0.6) 38.2 (0.7) 0.81
2–26 h after time 0 33.7 (0.2) 34.2 (1.4) 0.85
26–48 h after time 0 37.0 (0.8) 37.2 (0.3) 0.85
PaO2 (kPa)
Baseline 15.3 (6.2) 22.4 (20.0) 0.92
Insult nadir 4.9 (1.1) 6.3 (4.5) 0.77
12 h after time 0 15.2 (4.8) 12.1 (3.7) 0.36
24 h after time 0 20.2 (5.6) 15.1 (3.8) 0.13
48 h after time 0 23.5 (14.9) 23.3 (13.9) 0.63
PaCO2 (kPa)
Baseline 5.2 (1.4) 5.0 (0.6) 0.67
Insult nadir 5.3 (1.1) 4.6 (1.1) 0.10
12 h after time 0 5.7 (1.5) 6.9 (2.5) 0.50
24 h after time 0 5.5 (3.1) 4.5 (2.0) 0.96
48 h after time 0 6.0 (1.8) 5.7 (2.0) 0.63
Blood pH
Baseline 7.43 (0.06) 7.26 (0.68) 0.36
Insult nadir 7.35 (0.10) 7.39 (0.08) 0.12
12 h after time 0 7,42 (0.10) 7.38 (0.14) 0.63
24 h after time 0 7.44 (0.19) 7.52 (0.20) 0.29
48 h after time 0 7.35 (0.09) 7.42 (0.14) 0.27
Base excess (mmol/l)
Baseline 1.2 (4.8) 7.8 (4.7) 0.02
Insult nadir −4.1 (3.5) −2.0 (4.0) 0.33
12 h after time 0 2.2 (3.5) 4.1 (3.0) 0.31
24 h after time 0 0.6 (5.1) 2.1 (3.9) 0.87
48 h after time 0 −1.1 (4.1) 1.9 (4.2) 0.34
Lactate (mmol/l)
Baseline 4.28 (2.32) 2.62 (1.23) 0.08
Insult nadir 8.85 (2.38) 7.22 (2.17) 0.21
12 h after time 0 2.83 (1.46) 3.11 (2.21) 0.77
24 h after time 0 3.80 (3.53) 3.74 (1.92) 0.25
48 h after time 0 2.27 (2.30) 1.23 (0.63) 0.24
Glucose (mmol/l)
Baseline 6.6 (1.7) 5.6 (1.8) 0.16
Insult nadir 9.1 (2.3) 8.9 (2.0) 0.80
12 h after time 0 12.8 (4.7) 9.2 (4.8) 0.08
24 h after time 0 16.3 (7.8) 13.2 (7.4) 0.56
48 h after time 0 8.5 (3.9) 7.2 (3.8) 0.48
Time zero was set at the time of reperfusion/resuscitation. Mean and standard deviation
(SD) values are presented for the two groups; (i) Cooling (n = 10) and (ii) Cooling +
Argon (n = 8). Analysis using Mann–Whitney test indicated that there was no evidence
of a difference between the two groups for any of the outcomes at any of the time-points
apart from the baseline base excess was more alkaline in the Cooling + Argon group. In-
sult severity was estimated by calculating the time integral of the change in NTP/epp dur-
ing HI and the ﬁrst 60 min of resuscitation.
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and C.I.s are shown in Table 3. NTP/epp and PCr/Pi means were signiﬁ-
cantly higher at 48 h in Cooling + Argon compared to the Cooling
group (p = 0.01 for both). White matter Lactate/NAA was signiﬁcantly
lower in the Cooling + Argon compared to the cooling group at 24 and
48 h (p=0.03 and p=0.04 respectively). Thalamic 1HMRS showed no
differences between groups at any time point.
3.4. aEEG recovery was faster in the Cooling + Argon group
The group mean hourly aEEG scores were signiﬁcantly higher
(p b 0.05) in the Cooling + Argon versus Cooling group from 18 h
post hypoxia–ischemia onward, indicating faster recovery of brain elec-
trical activity towards normal with Argon-augmented cooling. The
overall difference between the means for the two treatment groups,
and treatment differences for each time interval are presented with
95% C.I.s (Table 4) and graphically using 95% Least Signiﬁcant Difference
error bars (Fig. 5).
3.5. Cooling + Argon decreased TUNEL positive cell death at 48 h
Representative photomicrographs of TUNEL staining in the putamen
and periventricular white matter are shown for Cooling and
Cooling + Argon are shown in Fig. 6A–D. The 95% C.I.s are shown in
Table 5. There was evidence of an overall difference between the
means of the Cooling versus Cooling + Argon treatment groups (p =
0.018) with the estimated cells per mm2 20.9 points lower (95% C.I.
3.7–38.2) for the Cooling + Argon versus Cooling alone. The estimated
mean cells per mm2 for the two treatment groups by region are
shown in Fig. 6E. The region showing the largest difference in cell
death was the putamen with a mean difference of 61.0 cells per mm2
(p = 0.01). The caudate showed a mean difference of 42.2 cells per
mm2 (p = 0.07) (Fig. 6F).
4. Discussion
Compared to cooling alone, we observed improved cerebral protec-
tionwith a combination of cooling and 45–50%Argon started at 2 h after
hypoxia–ischemia and continued for 24 h in our newborn piglet model
of perinatal asphyxia. The addition of Argon to cooling increased whole
brain ATP and PCr at 48 h (31P MRS NTP/epp and PCr/Pi) and reduced
the secondary rise in white but not gray matter Lac/NAA on localized
1H MRS at 24 and 48 h. Compared to cooling, the combined therapy
led to a faster aEEG recovery from18 h after hypoxia–ischemia and a re-
duction in cell death on TUNEL staining over seven brain regions com-
bined and in the putamen speciﬁcally.
OurMRS biomarkers correlate with injury severity after hypoxia–is-
chemia in the piglet (Lorek et al., 1994; Penrice et al., 1997) and out-
come in infants with NE (Robertson et al., 1999). Higher ATP on 31P
MRS in infants with NE is associated with better long-term outcome in
clinical studies (Azzopardi et al., 1989); we saw higher levels of ATP
with Argon-augmented cooling compared to cooling alone. High levels
of thalamic lactate/NAA on MRS in neonates in the ﬁrst month after
birth are predictive of a poor 12–18 month neurodevelopmental out-
come (Robertson et al., 1999; Thayyil et al., 2010); we saw reduced
Lac/NAA on white matter MRS with Argon-augmented cooling com-
pared to cooling alone. The aEEG background voltage and rate of aEEG
recovery after HI are also predictive of neurodevelopmental outcome
Table 2
Volume and inotrope requirements.
Treatment Cooling Cooling + Argon p value
Median (IQR)
Saline bolus ml/kg 0 (0,0) 1 (0,1) NS
Dopamine (μg/kg/min) 12.8 (8.9, 16.0) 17.3 (10.5, 18.5) 0.10
Dobutamine (μg/kg/min) 0 (0.1) 8 (0,11) 0.14
Adrenaline (ng/kg/min) 0 (0.7) 0 (0,6) NS
Mean (IQR) values for total volume replacement and dopamine, dobutamine and adrena-
line infusions. Analysis using Kruskal–Wallis equality of populations rank test revealed no
evidence of a statistically signiﬁcant difference between groups for volume replacement
and inotrope use. NS = not signiﬁcant.
Fig. 4.Magnetic resonance spectroscopy of the brain at baseline, 24 and 48 h after hypoxia-ischemia. Least squaresmeans plotwith 95% Least SigniﬁcantDifference (LSD) bars for the NTP/
epp and PCr/Pi in whole-forebrain, and Lac/NAA in thalamus and white matter; non-overlapping bars show evidence of a signiﬁcant difference. Whole-forebrain NTP/epp (A) and PCr/Pi
(B)meanswere signiﬁcantly higher in the Cooling+Argon group compared to Cooling at 48 h post-HI.Whitematter Lac/NAAwas signiﬁcantly lower in the Cooling+Argon group com-
pared to Cooling at both 24 and 48 h (p = 0.03 and p = 0.04 respectively). Thalamic 1H MRS showed no difference between groups at any time point. *p b 0.05, **p = 0.01. epp = ex-
changeable phosphate pool; Lac = lactate; NAA= N-acetyl aspartate; Thal = thalamic; WM=white matter; HI = hypoxia–ischemia.
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in NE (van Rooij et al., 2005) even in babies undergoing therapeutic hy-
pothermia, with a positive predictive value of an abnormal background
pattern of 0.82 at 48 h (Csekő et al., 2013). In our study, electrical activ-
ity on the aEEG normalized more rapidly with Argon and cooling from
18 h onwards compared to cooling alone.
Argon was not associated with any cardiovascular or blood pressure
changes during the 24 h delivery period and was well tolerated by all
piglets. This is in keepingwith the physiological stability seen in a recent
piglet safety study of inhaled Argon in concentrations up to 80%
(Alderliesten et al., 2014). In our study, Argon was straightforward to
deliver through a standard neonatal SLE 2000 ventilator with no re-
quirement for a scavenging system, unlike Xenon (Faulkner et al.,
2012). Despite its 200 fold higher cost and scarce supply, Xenon has
been more widely studied than Argon and has shown signiﬁcant brain
protection in adult (Schmidt et al., 2005) and neonatal (Ma et al.,
2005) pre-clinical studies of hypoxia–ischemia, particularly when com-
bined with cooling (Chakkarapani et al., 2010; Faulkner et al., 2011).
Clinical trials of Xenon as an additional treatment to hypothermia for
NE are underway in the UK (TOBYXe; NCT00934700 and Cool Xenon
study; NCT01545271). Although Xenon is an anesthetic at atmospheric
pressure and Argon is not, both noble gases share the important attri-
bute of good blood brain barrier penetration and fast onset, which are
vital properties for neuroprotection.
Protective effects of Argon have been seen in in vitro excitotoxic and
hypoxic models (Coburn et al., 2008; Jawad et al., 2009; Loetscher et al.,
2009). An in vivo adult rodentmodel of transientmiddle cerebral artery
occlusion (MCAO) exposed to 50% Argon 1 h after hypoxia–ischemia
showed a signiﬁcant overall reduction in infarct volume compared to
no Argon; this protectionwasmost marked in the cortex and basal gan-
glia (Ryang et al., 2011). Another MCAO study of found similar protec-
tion in the cortex with 50% Argon, but increased subcortical damage
and no improvement in neurological deﬁcit (David et al., 2012). In our
Argon piglet study we observed higher levels of ATP across the whole
brain on 31P MRS but more protection in the white matter than gray
matter voxel on 1H MRS. This is supported by the ﬁnding of improved
electrographic recovery on aEEG, as the white matter voxel captures
the dorsal aspect of the brain corresponding to EEG lead placement.
MRS voxel position may explain why gray matter protection was not
seen; the gray matter MRS voxels were centered on both thalami and
so did not samplemetabolism in the putamenwhere strong histological
cell protection was seen. As well as signiﬁcant histological protection in
the putamen, there was a trend towards protection in the caudate but
not in the thalamus. Histological protection was not seen in the white
matter regions — the internal capsule and periventricular white mater
(see Table 5 and Fig. 5); this may relate to the lower levels of cell
death with cooling and less opportunity for white matter protection
with the addition of Argon. Combining all brain regions therewas signif-
icant protection with the addition of Argon to cooling. A partial volume
effect of the white matter MRS voxel may have resulted in MRS sam-
pling of adjacent brain regions including areas of graymatter. Protection
observed with Argon in our current study appears more robust than
with Xenon in the same model in 2011 with a similar insult (Faulkner
et al., 2011); in this previous studywe observed no statistically signif-
icant difference between Xenon-augmented cooling and cooling
alone, although differences were seen when combined therapy was
compared with no therapy. Interestingly, histological protection
was also observed with Xenon augmented cooling in the putamen
(as seen with Argon) and the cortex, however this protection was
only signiﬁcant when compared to control animals not receiving
cooling (Faulkner et al., 2011).
There are several possible mechanisms thought to mediate Argon's
brain protection. As Argon (atomic number 18) is smaller than Xenon
(atomic number 54), this may change its binding sites. Argon triggers
gamma-aminobutyric acid (GABA) neurotransmission by acting at the
benzodiazepine binding site of the GABAA receptor (Abraini et al.,
2003), however this is seen typically under hyperbaric conditions and
the role of this pathway is unclear in the immature brain in which
GABA receptor activation is excitatory (Ben-Ari et al., 2012). Neverthe-
less, the activation of GABA receptors in mature brain has been shown
to be protective (Schwartz-Bloom and Sah, 2001). Argon has also been
seen to have oxygen-like properties where it increased survival in ani-
mals under hypoxic conditions (Soldatov et al., 2008); this may confer
mitochondrial protection in the post ischemic period. Anti-apoptotic
signaling is an important mechanism of Argon's brain protection. Like
Xenon, Argon increases expression of cell survival proteins; those spe-
ciﬁc to Argon are increased expression of Bcl-2 (Zhuang et al., 2012)
and enhancement of the ERK 1/2 activity in astrocytes, neurons andmi-
croglia by direct activation of the MEK/ERK 1/2 pathway (Fahlenkamp
et al., 2012). Argon reduces heat shock protein expression (Ulbrich
et al., 2015). Argon does not appear to inﬂuence NMDA receptors or po-
tassium channels (Brücken et al., 2014), which are two important
mechanisms of Xenon and hypothermic protection. The additive
Table 3
Summary of differences between Cooling and Cooling + Argon MRS results at 48 h.
Difference in means (log 10 scale)
Cooling–Cooling + Argon
95% C.I. for difference (log scale) Ratio of means (original scale) 95% C.I. for ratio (original scale) p-Value
NTP/epp −0.077 −0.13 to−0.02 0.84 0.74 to 0.95 p b 0.01
PCr/Pi −0.194 −0.33 to−0.05 0.64 0.46 to 0.89 p b 0.01
Thalamus Lac/NAA 0.259 −0.13 to 0.65 1.82 0.74 to 4.45 0.19
White matter Lac/NAA 0.490 0.02 to 0.96 3.09 1.04 to 9.18 0.04
The Cooling + Argon group showed higher levels of NTP/epp and PCr/Pi and lower white matter Lac/NAA compared to Cooling alone. epp = exchangeable phosphate pool; PCr =
phosphocreatine; Pi = inorganic phosphate; Lac = lactate; NAA= N acetyl aspartate. Bold emphasis indicates statistical signiﬁcance.
Table 4
Differences between the Cooling + Argon and Cooling group aEEG scores at the different time points.
Time interval relative to HI Difference in mean aEEG
(Cooling + Argon–Cooling)
Standard error of the difference Lower 95% C.I. for difference Upper 95% C.I. for difference p value
Baseline (before HI) −0.482 0.614 −1.701 0.736 0.434
0–6 h 0.299 0.614 −0.920 1.517 0.628
7–12 h 0.773 0.614 −0.446 1.991 0.211
13–18 h 1.542 0.625 0.301 2.782 0.015
19–24 h 1.502 0.718 0.076 2.927 0.039
25–30 h 1.324 0.625 0.084 2.565 0.037
31–36 h 1.244 0.662 −0.069 2.558 0.063
37–42 h 1.833 0.713 0.419 3.248 0.012
The Argon + Cooling group showed evidence of faster recovery of electrical activity compared to Cooling from the time period 13–18 h after hypoxia–ischemia onwards (p b 0.04 for all
intervals except for p = 0.06 for 31–36 h). HI: hypoxia–ischemia. Bold emphasis indicates statistical signiﬁcance.
35K.D. Broad et al. / Neurobiology of Disease 87 (2016) 29–38
protection seen with the combination of Argon and cooling suggests
that Argon targets complementary cell protection cascades to cooling,
unlike Xenon,which targetsmore similar cascades to cooling. For exam-
ple, one important action of cooling is to reduce glycine release after
hypoxia–ischemia (Illievich et al., 1994). Unlike Xenon, Argon has
been shown to have no effect on NMDA receptors at high or low glycine
levels (Harris et al., 2013). We did not study the effect of Argon-
augmented cooling on neuroinﬂammation. A recent rodent study
Fig. 5. Amplitude-integrated electroencephalogram (aEEG). The group mean hourly aEEG scores were signiﬁcantly higher in the Cooling + Argon group versus Cooling alone, from 18 h
post-HI onwards, indicating faster recovery of brain electrical activity towards normal. Panel A shows groupedmean hourly aEEG scores per 6-hour period with 95% Least Signiﬁcant Dif-
ference (LSD) where non-overlapping bars show evidence of a signiﬁcant difference. Representative aEEG traces are shown at 24 h post-HI for the Cooling (B) and Cooling + Argon
(C) groups. aEEG = amplitude-integrated EEG; HI = hypoxia–ischemia. *p b 0.05.
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found elevated expressions of several inﬂammatory cytokines (IL-1β,
IL-6, iNOS) and an increased expression of growth factors (TGFβ, NGF,
VEGF) following transientMCAO+Argon compared toMCAO+placebo
(Fahlenkamp et al., 2014).
The study has some limitations. We observed that the
Cooling + Argon group's blood pH was more alkaline at baseline than
the Cooling group. It is unclear why this occurred, however, both levels
arewithin the normal range for piglets and all included piglets appeared
Table 5
Differences between the Cooling + Argon and Cooling group TUNEL counts for all seven brain regions and overall.
Area Difference in mean TUNEL count
(Cooling–Cooling + Argon)
Standard error of the difference Lower 95% C.I. for difference Upper 95% C.I. for difference p value
Sensorimotor cortex 22.4 23.3 −23.5 68.4 0.338
Cingulate cortex 25.3 23.3 −20.7 71.3 0.279
Thalamus 10.4 23.3 −35.5 56.4 0.655
Caudate 42.2 23.3 −3.8 88.2 0.072
Putamen 61.0 23.3 15.0 107.0 0.010
Internal capsule 2.4 23.3 −43.5 48.4 0.917
Periventricular white matter 3.5 23.3 −42.5 49.5 0.880
Overall 20.9 8.8 3.7 38.2 0.018
The overall cell death in 7 regions was reduced in the Argon + Cooling group compared to the Cooling group, with the largest difference seen in the putamen and in the caudate. Bold
emphasis indicates statistical signiﬁcance.
Fig. 6. TUNEL histology. Co-treatment with 45-50% Argon decreased TUNEL-positive cell death at 48 h after a hypoxic ischemic insult when compared to cooling alone. Representative
sections are shown at ×20 magniﬁcation from the same animal in the Cooling (left column, A and C) and Cooling + Argon (right column, B and D) from the putamen (PTMN) and
periventricular white matter (pvWM). There was an overall decrease in the estimated mean TUNEL-positive cells per mm2 (pooled across region and R0/R1 levels) in the
Cooling + Argon group versus Cooling alone (E). On regional assessment, there was a signiﬁcant decrease in TUNEL-positive cells in the Putamen and evidence of a trend in the Caudate
in the Cooling + Argon group versus Cooling alone (F). *p b 0.01, †p = 0.07. Sensorimotor cortex = sTEX; Cingulate cortex = cTEX; Thalamus = THAL; Caudate nucleus = CDT;
Putamen= PTMN; Internal capsule = IC; Periventricular white matter = PvWM.
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healthy, with normal baseline blood lactate levels. Some in vitro studies
suggest there may be an additional effect of Argon at higher concentra-
tions than 50% (Ulbrich et al., 2014);we chose 50% as it has shownmax-
imal beneﬁt in some studies (Loetscher et al., 2009) and allows for the
inspired oxygen to be increased if required to maintain oxygen satura-
tions. In both Cooling and Argon + Cooling groups we saw higher
blood glucose during cooling; this may be due to the cooling itself as
cooling has been associated with increased blood glucose variability
and greater insulin requirements compared to the post-rewarming nor-
mothermic phase (Escolar et al., 1990). Finally, no formal corrections for
multiple measurements of MRS were made; the p values are indicators
of a signal that is likely to have biological and outcome signiﬁcance.
In summary, this is the ﬁrst study to show augmentation of hypo-
thermic neuroprotection in a neonatal pre-clinical large animal model
of birth asphyxia. 45–50% Argon was practical and easy to deliver and
was not associated with any physiological differences during the 24 h
exposure with cooling. Protection was assessed using biomarkers
(MRS and aEEG), which are strongly predictive of outcome in babies
with NE. The overall brain cell death was reduced with the addition of
24 h Argon to cooling and this protection was evident with a two-
hour delay starting therapy. Argon may be an affordable and practical
therapy to augment hypothermic brain protection in babies with NE.
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